• Back to Kidney Cancer Panel

• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011 Jul-Aug;48 (4):155-70
• Aziz-Seible RS, Casey CA. Fibronectin: functional character and role in alcoholic liver disease. World J Gastroenterol. 2011 May 28;17 (20):2482-99
• Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007 Oct 30;116 (18):2029-35
• Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988 Sep 1;335 (6185):88-9
• Clark RA, Lanigan JM, DellaPelle P, Manseau E, Dvorak HF, Colvin RB. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol. 1982 Nov;79 (5):264-9
• Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, Straka RJ, Province M, Lai CQ, Parnell LD, Borecki I, Ordovas JM. The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem. 2007 Jun;53 (6):1144-52
• Deichmann M, Benner A, Waldmann V, Bock M, Jackel A, Naher H. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res. 2000 Sep;19 (3):301-7
• Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 Nov 11;302 (18):1993-2000
• Fan H, Yuan Y, Wang J, Zhou F, Zhang M, Giercksky KE, Nesland JM, Suo Z. CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome. Histopathology. 2013 Jun;62 (7):1028-37
• Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem. 2000 Jul;46 (7):934-8
• Hynes RO, Yamada KM. Fibronectins: multifunctional modular glycoproteins. J Cell Biol. 1982 Nov;95 (2 Pt 1):369-77
• Jiang ZH, Zhang ZY, He M, Qin J, Wang Q, Wei X, Nong BJ, Liu F. [The screening and identification of Apolipoprotein A-II from serum differential proteins in hepatocellular carcinoma patients]. Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18 (6):445-9
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008 Sep;53 (3):245-66
• Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Marquez S, Gonzalez-Sastre F, Chan L. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996 Mar 22;271 (12):6720-8
• Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morph. 2005 Sep;13 (3):205-20
• Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002 Oct 15;115 (Pt 20):3861-3
• Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;111 (12):1805-12
• Remaley AT. Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?. Arterioscler Thromb Vasc Biol. 2013 Feb;33 (2):166-7
• Salazar J, ORCID: 0000-0003-4211-528X, Martinez MS, Chavez M, ORCID: 0000-0001-8511-0230, Toledo A, Anez R, Torres Y, Apruzzese V, Silva